Sinovac Raises $86.73 Million Through Private Placement Transaction
Vivo Capital and Advantech Capital Each Hold an Approximately 8.3% Stake in Sinovac After the Private Placement Transaction- Proceeds Will Be Used to Fund Improvement and Construction of Facilities for R&D Relating to Quality Control and Production of New Vaccines Projects
- Sinovac's Board of Directors Terminates the Amalgamation Agreement to Take the Company Private
The Company also today announced the termination of the Amalgamation Agreement to take the Company private, previously entered into on
"This PIPE transaction will improve Sinovac's capability to continue its mission of researching, developing, manufacturing and commercializing vaccines that protect against human infectious diseases," said Mr.
Now that funding is secured, the Company is commencing plans for new production and research facilities to support the development and commercialization of sIPV-based combination vaccine and other new vaccine projects. According to the
Houlihan Lokey served as financial advisor, and
About Sinovac
Safe Harbor Statement
This announcement may include certain statements that are not descriptions of historical facts, but are forward-looking statements. These statements are made under the "safe harbor" provisions of the
View original content:http://www.prnewswire.com/news-releases/sinovac-raises-86-73-million-through-private-placement-transaction-300675823.html
SOURCE
A.M. Best to Sponsor 2018 International Insurance Society’s Global Insurance Forum
American Fidelity Selects 7SIGNAL to Enhance Wi-Fi Experiences
Advisor News
Annuity News
Health/Employee Benefits News
Life Insurance News